Combination Is Active in Prostate Cancer
Durvalumab and Lynparza (olaparib) provided a response for patients in a small study.
PUBLISHED February 21, 2017
The PD-L1 inhibitor durvalumab and the PARP inhibitor Lynparza (olaparib) provided a response for about half of the patients with metastatic castration-resistant prostate cancer (mCRPC) in a small study, according to the preliminary results of an ongoing trial.
Overall, eight out of 10 patients had a reduction in PSA level, including five patients who had declines in PSA tests exceeding 50 percent or more from baseline. The cohort had a median progression-free survival (PFS) of 7.8 months.
Among seven patients followed for more than two months, grade 3/4 adverse events (AEs) consisted of two cases of anemia and one each of thrombocytopenia, lymphopenia, neutropenia, nausea, fatigue, urinary tract infection and lung infection, as reported at the 2017 Genitourinary Cancers Symposium in Orlando.
“The preliminary data show that the combination of durvalumab and Lynparza is well tolerated and has activity in an unselected population,” Fatima Karzai, M.D., an investigator at the National Cancer Institute, and colleagues concluded in a poster presentation. “Paired tumor biopsies and blood samples are being collected to examine potential biomarkers of response.” Accrual to a total of 25 patients is ongoing, she added.
About 30 percent of patients with sporadic mCRPC harbor somatic or germline mutations in DNA-repair genes, suggesting sensitivity to PARP inhibition. Enzalutamide-resistant prostate cancer expresses PD-L1, but limited data have accumulated regarding the safety and efficacy of PD-L1 inhibition in mCRPC.
Investigators hypothesized that increased DNA damage induced by PARP inhibition would complement the antitumor activity of durvalumab in mCRPC. To test this hypothesis, they enrolled patients with previously treated mCRPC who progressed following the most recent therapy.
The trial had a primary objective of PFS. Secondary objectives included overall response rate, safety, PSA response, and duration of response. As an exploratory objective, investigators examined the relationship between levels of circulating tumor cells and clinical outcomes.
The 10 patients included in the report by Karzai and colleagues had a median age of 65, and nine out of the 10 had an ECOG performance status of 1. One patient had previously received Zytiga (abiraterone), four had received Xtandi (enzalutamide) and five had received both drugs. Additionally, four patients had been treated with Provenge (sipuleucel-T), one with PROSTVAC, and one with both agents. Five patients had previously received docetaxel (Taxotere) for metastatic disease.
The best PSA responses ranged from a decline of 15 percent to a decline of 99 percent. Other patients had declines from baseline of 94 percent, 79 percent, 73 percent and 59 percent. Responses were observed in patients who had only bone metastases, and in those who had bone plus soft-tissue/visceral metastases, regardless of the number of prior lines of therapy, and in patients with or without mutations in DNA repair pathways.